Novo Nordisk A/s

Peter Kresten Nielsen

Jesper F Lau

Thomas Kruse

Henning Thoegersen

Ulrich Sensfuss

Per Balschmidt

Frantisek Hubalek

Svend Ludvigsen

Inger Lautrup-Larsen

Patrick William Garibay

Svend Havelund

Tina Moeller Tagmose

Birgit Wieczorek

Thomas Børglum Kjeldsen

Tina Møller Tagmose

Kilian Waldemar Conde Frieboes

Ulla Ribel-Madsen

Subhash R Patel

Henning Borge Petersen

Xujia Zhang

Birgitte Andersen

Per Nørgaard

Rita Slaaby

Michael Cain

Henning THØGERSEN

Kristian Sass Bak-Jensen

Helle Fabricius Woeldike

Jishu Wang

Helle WÖLDIKE

The invention relates to derivatives of glucagon analogs comprising the substitutions Imp1 and His3, a substituent having three to ten negatively charged moieties covalently attached to a side chain of a lysine as well as intermediates and compositions thereof and their use in medicine.

Stable glucagon analogues and use for treatment of hypoglycaemia

Analogs of FGF21 carrying a modifying, substituted ethylene or benzyl group can be used for treatment or prevention of diabetes, dyslipidemia, obesity, cardiovascular diseases, metabolic syndrome, and/or Non Alcoholic Fatty Liver Disease (NAFLD).

N-terminal modified FGF21 compounds

The present invention relates to novel glucagon peptides, to the use of said glucagon peptides in therapy, to methods of treatment comprising administration of said glucagon peptides to patients in need thereof, and to the use of said glucagon peptides in the manufacture of medicaments. The glucagon peptides of the present invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity.

Glucagon analogues

The present invention relates to novel insulin analogs comprising mutations at position A14 in the A chain and at positions B27, B28, B29 and B30 in the B chain and exhibiting resistance towards protease; a method for the preparation of such insulin analogs; insulin preparations containing the insulin analogs of the invention; and, a method of treating diabetes mellitus using these insulin analogs.

Protease-stabilized insulin analogues

The present invention relates to novel insulin analogues exhibiting resistance towards protease, wherein at least two amino acids are substituted and/or deleted relative to the parent insulin molecule. A method for the preparation of such insulin analogues, insulin preparations containing the insulin analogues of the invention and a method of treating diabetes mellitus using these insulin analogues is also provided.

Protease resistant insulin analogues

The invention provides crystalline Tiagabine hydrochloride monohydrate, process for its preparation, compositions containing the same and its therapeutic use as anti-epileptic agent.

Crystalline Tiagabine monohydrate, its preparation and use

Growing community of inventors

Holte, Denmark

Peter Kresten Nielsen